MONTREAL, QUEBEC--(Marketwire - Nov. 14, 2011) - MethylGene Inc. (TSX:MYG) announced that it has presented results for the Company's Phase 1 clinical trial (Trial 265-102), in which MGCD265 was administered as a single agent on an intermittent schedule ... MethylGene Reports Clinical Data for MGCD265 at the 2011 AACR-NCI- EORTC ...
Sunday, November 13, 2011
MethylGene Reports Clinical Data for MGCD265 at the 2011 AACR-NCI- EORTC ...
MONTREAL, QUEBEC--(Marketwire - Nov. 14, 2011) - MethylGene Inc. (TSX:MYG) announced that it has presented results for the Company's Phase 1 clinical trial (Trial 265-102), in which MGCD265 was administered as a single agent on an intermittent schedule ... MethylGene Reports Clinical Data for MGCD265 at the 2011 AACR-NCI- EORTC ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment